Lonza: Positive start to 2018, driven by expanding healthcare businesses

04 May 2018 --- Lonza has reported a “positive” start to 2018 led by the businesses along the healthcare continuum. The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, has shown a strong performance following good progress on business and functional integration, the company reports, without giving any details on financial figures. For the coming months, Lonza has announced plans to expand facilities in the US.

Nexira enters strategic partnership for nutritionals, not giving up its acquisition plans

02 May 2018 --- Nexira, a global leader in natural and organic ingredients for the food, health and nutrition industries, has announced a strategic partnership agreement with Omega Pharma NV, one of the largest OTC healthcare companies in Europe and Inqpharm Group (a Zaluvida company), a specialty pharmaceutical company.

Fermentalg reports on Q1 revenue as US expansion begins

20 Apr 2018 --- Fermentalg, a French supplier of microalgae for nutrition and health, has reported first-quarter revenue of €232k whereas no income was recorded in Q1 2017. As of 31 March 2018, Fermentalg held gross cash and cash equivalents of €19.5 million compared to €21.8 million at 31 December 2017. Cash burn amounted to a €2.5 million outflow, stable compared to the previous quarter (excluding financing activities) and down €0.5 million from Q1 2017. Q1 was marked by progress achieved in bringing to market its DHA ORIGINS range of algal oils naturally rich in omega 3, as well as a US distribution agreement with Stauber, a leading North American supplier of specialty ingredients, the company reports. 

GSK to take full ownership of Novartis stake in Consumer Healthcare Business for US$13bn

27 Mar 2018 --- GlaxoSmithKline (GSK) has reached an agreement with Novartis for the acquisition of Novartis’ 36.5 percent stake in its Consumer Healthcare Joint Venture for US$13 billion, just days after GSK exited the race to buy Pfizer's Consumer Healthcare Business. GSK reports that the Consumer Healthcare Business is well positioned to drive sales and earnings growth, powered by “category-leading Power Brands, science-based innovation and improved efficiencies.” Novartis reports that the sale will enable it to further focus on the development and growth of its core businesses.

"Aggressive transformation": Nellson announces US$70m investment in new facility

16 Mar 2018 --- A US$70 million investment in a new nutrition bar manufacturing plant in Ontario, California has been announced by Nellson Nutraceutical (Nellson), a North American formulator and manufacturer of branded and private label nutritional bars and functional powders. 

Ancient becomes modern: US$103 million investment for bone broth innovator

12 Mar 2018 --- Ancient Nutrition, a bone broth protein and collagen supplement maker, has secured $103 million in funding through strategic minority investment led by VMG Partners. The company, which is the breakthrough pioneer in Bone Broth Protein supplementation that delivers the benefits of “homemade bone broth in a convenient, easy-to-mix form,” revealed a minority investment from VMG Partners, Hillhouse Capital, ICONIQ Capital, and over 100 members of a co-investor network.

Gelita develops controlled soft gelatin capsule fill release

12 Mar 2018 --- Gelita is offering manufacturers of soft gelatin capsules the opportunity to see first hand the complete spectrum of capsule fill release profiles – including the latest addition to Gelita’s pharmaceutical gelatin portfolio: Gelita EC for enteric performance.

Lonza to expand Florida encapsulation capabilities amid product development acceleration

21 Feb 2018 --- Swiss multinational, chemicals and biotechnology company, the Lonza Group is planning to expand its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company will install a new Harro Hӧfliger Modu-C MS encapsulation unit (Harro unit) at its integrated product development and manufacturing facility in Tampa, Florida, to strengthen production and bring its products to market faster. 

Dynamic OTC marketplace: Albertsons and Rite Aid merge, Amazon enters the fray

21 Feb 2018 --- Albertsons Companies, one of the US’ largest grocery retailers, and leading drugstore chain Rite Aid Corporation have announced a definitive merger agreement, creating a retail behemoth with US$83 billion in annual revenue. The move is thought to give the integrated company more weight to compete with bigger chains in an industry anxious about the reported entry of Amazon.com.

AI and personalized nutrition: Nestlé and Nuritas partner on bioactive peptide development

09 Feb 2018 --- Nestlé and biotech company Nuritas have entered into a collaboration aiming to uncover bioactive peptide networks within “specific target areas of significant value.” The precise areas of investigation are not yet being shared, with Nuritas Commercial Manager Neil Foster telling NutritionInsight that these details and the expected launch date are “at this early stage understandably confidential.” As part of the collaboration, Nuritas is to deploy its novel technology platform, which uses Artificial Intelligence and DNA analysis to predict, unlock and validate highly efficacious peptides, exclusively from natural food sources. Nestlé will use their considerable scientific know-how and applications expertise to validate the efficacy of these discoveries within the target applications.

Fermentalg acquires portfolio of omega 3 production patents in bid to strengthen technological position

06 Feb 2018 --- French microalgae supplier Fermentalg has acquired a portfolio of patents to reinforce its intellectual property and industrial and commercial capabilities in the field of omega 3 production. Fermentalg now owns a portfolio of five patents, some of which have already been issued in several countries, to add to its 21 families of active patents already filed. The company has also acquired a number of microalgae strains to add to its bank of over 2,000 strains which is one of the largest in the world.

Consumer health care: Nestle loses interest in Merck's OTC unit 

05 Feb 2018 --- Nestle has pulled out of the bid for Merck’s consumer health unit, leaving the race to buy the maker of Seven Seas vitamins and various other nutritional supplements without its main contender, Reuters reports. The news came a week after Johnson & Johnson withdrew from the race to buy US drugmaker Pfizer’s consumer health business, leaving Nestlé, GlaxoSmithKline and Reckitt Benckiser among the potential bidders. 

Fermentation focus: Naturex and Cura sign distribution agreement for koji fermented minerals

31 Jan 2018 --- Naturex has signed a global distribution agreement via its Open Innovation program (Ingenium) with Ames-based Cura for their Koji Minerals line of fermented minerals for the dietary supplement and functional food markets. This year’s launches based on Koji fermentation are a stand-alone iron with optimal bioavailability and slow release effect (results supported by two clinical studies) and a blend of seven minerals (iron, zinc, copper, manganese, selenium, molybdenum, chromium) particularly suitable for the multi minerals segment, Naturex reports.

Nestlé and GSK among potential bidders for Pfizer's consumer health unit, after J&J pulls out of race

29 Jan 2018 --- Johnson & Johnson has withdrawn from the race to buy US drugmaker Pfizer’s consumer health business, leaving Nestlé, GlaxoSmithKline and Reckitt Benckiser among the potential bidders, according to Reuters. Pfizer wants to sell the business, which makes Advil painkillers, Centrum multivitamins and Chapstick lip balm, for no less than US$20 billion, sources have told Reuters. The deadline to submit non-binding offers for the unit is on Thursday.

Antibiotic innovation: Research group calls for 50 percent investment increase as resistance threats intensify

22 Jan 2018 --- The World Health Organization (WHO) has deemed antibiotic resistance to be one of the three greatest threats to human health today, as bacteria become increasingly resistant and too few treatments are being developed to combat them. The research project DRIVE-AB, a consortium managed by the University of Geneva (UNIGE) and AstraZeneca, has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years.

Frutarom takes full ownership of Enzymotec, sells krill oil business to Aker BioMarine

19 Jan 2018 --- Frutarom Industries has completed its acquisition of full ownership of Enzymotec. Upon completion of the transaction on January 11, 2018, Enzymotec shares were delisted from trading on NASDAQ and it ceased to be a public company. Frutarom reports that it is working towards implementing the full merger plan of all Enzymotec activities through the rapid, efficient and comprehensive integration of both companies’ activities in the areas of management, R&D, sales and marketing, production and supply chain. As part of its merger plan, Frutarom has announced the sale of Enzymotec’s krill oil business to Aker BioMarine.

Bayn Europe sets up subsidiary in China for sugar reduction

15 Jan 2018 --- Bayn Europe AB has signed a joint venture agreement with real estate development company HuaHe International Asset Management Ltd. to introduce sugar reduction to the China market. Both partners have agreed on a cooperation model and mutual commitments for the set-up of the joint venture. Under the agreement, Bayn is to hold 65 percent of equity and HuaHe 35 percent. 

Nuritas raises €16m in Series A funding

21 Dec 2017 --- Nuritas has announced the close of a circa €16 million (US$19 million) Series A funding round led by Chicago-based Cultivian Sandbox Ventures. This brings the total invested to date to approximately €25 million, the company reports. The latest round of funding will support Nuritas’ global growth to address and solve many of the most pressing health issues of the day, including the diabetes epidemic. 

Cargill launches low saturated fat, high oleic canola oil

20 Dec 2017 --- Cargill has introduced the lowest saturated fat, high oleic canola oil available to commercial food customers worldwide. The oil is made from a canola hybrid that contains 4.5 percent or less saturated fat while maintaining high fry and shelf life performance, freshness and taste. It reduces saturated fat content 35 percent from previous canola oil generations, the company reports.

Nutrition industry “feels positive” about new EU rules for novel foods: survey

19 Dec 2017 --- According to research by the organizers of Vitafoods Europe, many people working in the nutrition industry feel positive about the EU’s new process for the approval of novel foods. However, experts are warning that there could be adverse implications for some companies’ intellectual property portfolios. The new regulations on novel foods, defined as anything without a significant history of consumption in the EU before 15 May 1997, come into force on 1 January 2018. For the first time, the approval system will be centralized, with applications submitted to the European Commission rather than individual member states.

loading